Alliance Growers is organized into four divisions: Cannabis Botany Centre, Strategic ACMPR Investments, CBD Oil Supply & Distribution, and Research & Development – in order to maximize the company’s potential for success in the medical marijuana marketplace.
Alliance Growers has partnered up with WFS Pharmagreen to start constructing a new botany centre in Mission, BC.
Pharmagreen’s new subsidiary, BC New Co, will build and operate the cannabis botany centre. Alliance Growers has entered into a binding Letter of Intent with WFS Pharmagreen Inc. to acquire an equity stake in Pharmagreen’s subsidiary BC New Co. Alliance Growers will purchase a non-dilutive 30% equity interest in BC New Co, bringing their project revenue share to 30%. The first 15% will be purchased by March 15, 2018 and the remaining 15% will be purchased by June 15, 2018.
Pharmagreen has already purchased the land upon which the proposed cannabis botany centre will be built in Mission, BC.
Botanical Research In Motion (B.R.I.M.) has granted Alliance Growers the use of its patented Chibafreen process for the production of plantlets from selected plant tissue at the Cannabis Botany Centre. The facility will also house a cold storage area utilizing the one-of-a-kind Cryotissue Cold Storage technology for long-term preservation of plant tissue samples.
The development of the Cannabis Botany Centre will add value to Alliance Growers by providing the potentially for three million cannabis plantlets per year with a potential margin of $4 per plantlet.
Through a serious of strategic partnerships and investments under negotiation with Licensed Producers at various stages in the license process, Alliance Growers is focused on securing long term plantlet sale contracts for the Cannabis Botany Centre and off-take agreements at wholesale cost for flower to be acquired by Alliance Growers for CBD oil extraction.
Alliance Growers has entered into an exclusive agreement to acquire Biocannatech which is to become a licensed producer under Health Canada’s “Access to Cannabis for Medical Purposes Regulations” (ACMPR). Incorporated in and located in Côte Saint-Luc, Québec, Biocannatech is in the final expedited phase of the ACMPR approval for the production and sales of Medical Marijuana. The company has applied to Health Canada for the building of a 10,000 sq. ft. facility with an attached 120,000-sq. ft. warehouse. Projected Gross Revenue is 10 Million per year and with additional approval the facility can be expanded to 70,000 square feet. Projected gross revenue of the expanded facility stands at $70 million per year. The primary construction phase is targeted for March 2018 and facility’s expansion estimated to be operational in late 2019.
Alliance Growers has negotiated terms on a 5% non-dilutive interest in New Maple Holdings, the parent company of its wholly owned subsidiary Canwe. Canwe is a private Ontario-based company that has applied for a producer’s license under the ACMPR. The company has access to a 22 acre property 1.5 hours north-west of Toronto, where it plans to build a facility focused on producing clean, premium quality cannabis. Canwe has amassed a stellar team which includes licensed producer MedReleaf Corp.’s former Head Grower Jack Yu, an expert cannabis growers who intimately knowledgeable in the cultivation of cannabis from seed to sale.
Alliance Growers plans are to continue seeking out further strategic investment opportunities in additional ACMPR companies to secure plantlet sales and CBD offtake agreements.
Alliance Growers is also in discussions for the joint development of 50 hectares of land for the growth of high quality cannabis plants, as legally permitted in an offshore, low operating cost jurisdiction. It is anticipated that the majority of the plant production would be processed for the extraction of pharmaceutical grade CBD Oil. This would facilitate the importation of cannabis products into various U.S. states, Canada (when legalized), and other countries as legally permitted.
ArcView Market Research released its fourth edition of The State of Legal Marijuana Markets report, and it includes the prediction that the legal cannabis market will see $21.8 billion in total annual sales by 2020.
Alliance Growers’ goal is to become a world leader in the production and supply of pharmaceutical grade cannabidiol (CBD) oil. To accomplish this goal Alliance has completed an agreement with Pharmagreen to build and operate a world class botany centre which includes a facility for extraction and processing of CBD oil.
Alliance Growers is finalizing an agreement with an Israeli medical cannabis company for a 20% equity investment to developing pharmaceutical grade CBD oil . Israeli government has encouraged cannabis research since the 1960’s and in 2017 the government announced it is investing $2.13 million in new research projects.
Israel’s Health Ministry’s Medical Cannabis Unit believes cannabis should be considered in the same manner as any other medicinal product. Licensed suppliers provide cannabis to Israel’s roughly 26,000 registered patients, creating a domestic market of about $15 million to $20 million.
Hebrew University researchers synthesized 22 versions of the cannabinoid molecule that have great potential for treating neurological and inflammatory diseases. After some success in using substance to treat epileptics, researchers will launch clinical trials to check the effect of cannabis oils on individuals with severe behavioral problems such as autism.
International companies regularly join forces with Israeli academic and medical institutions to create new medications. In February of 2017, a government committee approved a plan that would allow medical marijuana companies to export products internationally.
The Hemp Business Journal reports that the CBD market is growing at a rate of 30% per annum, and forecasts that sales of CBD Oils from marijuana-based sources are expected to reach $1,650,000,000, or- 79% of the Total CBD Market of $2,100,000,000 by 2020.
Generated revenue from the extraction, processing, and resale of cannabidiol (CBD) oil in Canada, USA, and offshore producers is estimated at several million dollars per year.
Through Botanical Research In Motion International Inc. (B.R.I.M.), under the guidance of Peter Wojcik and Dr. Fawzia Afreen, Alliance Growers will thoroughly pursue research and development to meet the demands of the ever changing medical cannabis industry.
Alliance Growers has already secured use of B.R.I.M.’s proprietary, state of art Chibafreen in-vitro plant production technology.
Utilizing clean tissue culture from existing plant strains, this process can produce ready to grow plantlets based on the original. The Chibafreen process is efficient enough to produce over one million plantlets per year and can be adapted to all varieties of flora potentially serving the entire agricultural industry.
B.R.I.M. has also developed a one-of-a-kind, proprietary Cryotissue Cold Storage technology for long-term preservation and regeneration of plant tissue samples. This feature will provide cultivators with the ability to preserve desired plant breeds and have plantlets produced as needed.
Alliance Grower has secured access to a propriety CBD strain, named “CBD DANA”. With a tested content of 10% plus CBD, and THC of less than .3%; CBD DANA is a unique strain with its high CBD and low THC content. This makes it ideal for cultivation as an “Industrial Hemp Plant” label, and therefore an optimal strain for Industrial Hemp farming. This strain will be one of the flagship strains for CBD Hemp farming and the female plantlets produced in the Tissue Culture Lab within the Cannabis Botany Center will be available for hemp farmers on a global scale. The Cannabinoids are mainly produced in the flower portion of the female plant, therefore planting female plantlets instead of planting from seed eliminates the males and keeps the flower production at maximum. Providing Hemp farmers all female, fully rooted plantlets, of “CBD DANA” will provide a significant yield in CBD production for hemp farmers. This is because the content is 1000 times or higher than traditional Hemp strains with 1% CBD content. Additional increase in the CBD yields is achieved when no males are present to pollinate the females which increases the flower content by an additional 80%.